Program
tifeglipron
Also written as “RO7795081”, “Tifeglipron” and “CT-996”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by Hoffmann-La Roche.
Furthest: phase 2, since Jul 22, 20256 company-led studies, 4 open or runningNext primary completion: Dec 7, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 64 open or running | phase 2since Jul 22, 2025 | Feb 23, 2023 | Dec 7, 2026phase 1 · NCT06982131 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6652 tifeglipron
, phase 2, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 23, 2023First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05814107 · 94 enrolled · Australia, Mexico
- May 13, 2025Phase 1 study in OverweightNCT06982131 · 40 enrolled · Netherlands
- Jul 22, 2025Phase 2 study in ObesityNCT07081958 · 352 enrolled · United States
- Aug 1, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07112872 · 330 planned · United States, Hungary, Poland and more
- Mar 23, 2026Phase 1 study in OverweightNCT07499050 · 30 enrolled · China
- Jul 29, 2026Phase 1 study in Renal InsufficiencyNCT07741604 · 60 planned · United States
- Oct 1, 2026Primary completion moved from 2026-11-27 to 2028-02-05Date moved laterphase 2 · +14 months · NCT07112872
Ahead
- Dec 7, 2026Primary completion: phase 1 study in OverweightNCT06982131
- Jan 9, 2027Primary completion: phase 1 study in OverweightNCT07499050
- Feb 1, 2028Primary completion: phase 1 study in Renal InsufficiencyNCT07741604
- Feb 5, 2028Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07112872
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07741604Renal Insufficiency · United States | 1 | Recruiting | Feb 1, 2028 | 60 |
| NCT07499050Overweight · China | 1 | Active, not recruiting | Jan 9, 2027 | 30 |
| NCT07112872Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more | 2 | Recruiting | Feb 5, 2028 | 330 |
| NCT07081958Obesity · United States | 2 | Completed | Apr 28, 2026 | 352 |
| NCT06982131Overweight · Netherlands | 1 | Active, not recruiting | Dec 7, 2026 | 40 |
| NCT05814107Diabetes Mellitus, Type 2 · Australia, Mexico | 1 | Completed | Nov 7, 2025 | 94 |
How it is read
Names in the registry
- “RO7795081”, 3 entries
- “Tifeglipron”, 2 entries
- “CT-996”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 3 studies
- Diabetes Mellitus, Type 2, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.